NL300917I1 - Midostaurine, desgewenst in de vorm van een zout - Google Patents
Midostaurine, desgewenst in de vorm van een zoutInfo
- Publication number
- NL300917I1 NL300917I1 NL300917C NL300917C NL300917I1 NL 300917 I1 NL300917 I1 NL 300917I1 NL 300917 C NL300917 C NL 300917C NL 300917 C NL300917 C NL 300917C NL 300917 I1 NL300917 I1 NL 300917I1
- Authority
- NL
- Netherlands
- Prior art keywords
- warm
- treatment
- midostaurine
- salt
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47957503P | 2003-06-18 | 2003-06-18 | |
| EP04740016A EP1638574B1 (en) | 2003-06-18 | 2004-06-17 | New pharmaceutical uses of staurosporine derivatives |
| PCT/EP2004/006562 WO2004112794A2 (en) | 2003-06-18 | 2004-06-17 | New pharmaceutical uses of staurosporine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300917I1 true NL300917I1 (nl) | 2017-12-12 |
| NL300917I2 NL300917I2 (nl) | 2018-01-09 |
Family
ID=33539193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300917C NL300917I2 (nl) | 2003-06-18 | 2017-12-07 | Midostaurine, desgewenst in de vorm van een zout |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8575146B2 (nl) |
| EP (1) | EP1638574B1 (nl) |
| JP (2) | JP5057780B2 (nl) |
| CN (2) | CN100457111C (nl) |
| AT (1) | ATE464052T1 (nl) |
| AU (1) | AU2004248909B2 (nl) |
| BE (1) | BE2017C067I2 (nl) |
| BR (1) | BRPI0411563B8 (nl) |
| CA (2) | CA2527703C (nl) |
| CY (2) | CY1110179T1 (nl) |
| DE (1) | DE602004026578D1 (nl) |
| DK (1) | DK1638574T3 (nl) |
| ES (1) | ES2344700T3 (nl) |
| FR (1) | FR17C1063I2 (nl) |
| HK (1) | HK1095519A1 (nl) |
| HU (1) | HUS000503I2 (nl) |
| LU (1) | LUC00055I9 (nl) |
| MX (1) | MXPA05013722A (nl) |
| NL (1) | NL300917I2 (nl) |
| PL (1) | PL1638574T3 (nl) |
| PT (1) | PT1638574E (nl) |
| SI (1) | SI1638574T1 (nl) |
| TW (1) | TWI324604B (nl) |
| WO (1) | WO2004112794A2 (nl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
| SI1686997T1 (sl) | 2003-11-18 | 2009-08-31 | Novartis Ag | Inhibitorji mutantne oblike KIT |
| WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| CN101022799A (zh) * | 2004-07-19 | 2007-08-22 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| GB0419159D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| MX2007013741A (es) * | 2005-05-02 | 2008-01-21 | Novartis Ag | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica. |
| BRPI0613863A2 (pt) * | 2005-07-20 | 2011-02-15 | Peter Valent | composições para tratamento de mastocitose sistêmica |
| AU2006313724B2 (en) * | 2005-11-14 | 2010-12-23 | Universitat Zurich | Staurosporine derivatives for use in alveolar rhabdomyosarcoma |
| WO2009092442A1 (en) * | 2008-01-23 | 2009-07-30 | Universidad De Barcelona | Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways |
| WO2012064981A2 (en) * | 2010-11-10 | 2012-05-18 | National Jewish Health | Methods to test allergic conditions |
| KR20210118812A (ko) | 2018-11-01 | 2021-10-01 | 사이로스 파마수티컬스, 인크. | 시클린-의존성 키나제 7 (cdk7)의 억제제 |
| WO2020097261A1 (en) * | 2018-11-06 | 2020-05-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and methods for treating beta-globinopathies |
| US11839619B2 (en) * | 2019-09-16 | 2023-12-12 | The Regents Of The University Of California | Methods for treatment of pediatric systemic mastocytosis |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639455A (en) * | 1984-10-02 | 1987-01-27 | Key Pharmaceuticals, Inc. | Means of aiding in the prevention of sudden infant death syndrome |
| JPH0826037B2 (ja) | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質ｋ−２５２の誘導体 |
| US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| CA2046801C (en) | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
| DE122007000073I1 (de) | 1991-05-09 | 2008-01-31 | Neurim Pharma 1991 | Melatonin enthaltene Arzneimittel |
| AR004480A1 (es) * | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
| JP2000514420A (ja) * | 1996-06-25 | 2000-10-31 | セファロン・インコーポレイテッド | 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用 |
| US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
| WO1999062537A1 (en) * | 1998-06-04 | 1999-12-09 | The Rockefeller University | Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins |
| GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| ATE301661T1 (de) * | 2000-12-08 | 2005-08-15 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
| GB0108606D0 (en) | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
| US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
| JP2004536097A (ja) * | 2001-06-29 | 2004-12-02 | アブ サイエンス | 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
| KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
| US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US20060217368A1 (en) | 2003-04-18 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Drug for nerve regeneration |
| EP1637161A4 (en) * | 2003-04-22 | 2007-06-27 | Astellas Pharma Inc | MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST |
| TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| SI1686997T1 (sl) | 2003-11-18 | 2009-08-31 | Novartis Ag | Inhibitorji mutantne oblike KIT |
-
2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 CA CA2527703A patent/CA2527703C/en active Active
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active Application Discontinuation
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en active Active
- 2004-06-17 CA CA2785950A patent/CA2785950A1/en not_active Abandoned
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/en active Application Filing
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh active Active
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es active Active
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja active Active
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de active Active
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
- 2004-06-17 EP EP04740016A patent/EP1638574B1/en active Active
-
2007
- 2007-01-18 HK HK07100635.4A patent/HK1095519A1/xx unknown
-
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
-
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
-
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
-
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I1/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300917I1 (nl) | Midostaurine, desgewenst in de vorm van een zout | |
| DK1611088T3 (da) | Hydroxymater som terapeutiske midler | |
| ATE520668T1 (de) | Sigmarezeptor-inhibitoren | |
| MY140826A (en) | Substituted pyrazoline compounds, their preparation and use as medicaments. | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| ATE517882T1 (de) | Chinolinderivate | |
| TW200626576A (en) | Bicyclic amides as kinase inhibitors | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| EA201390353A1 (ru) | Производное пиразолохинолина | |
| MX2009005622A (es) | Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores. | |
| TW200738699A (en) | 4-Substituted pyrazoline compounds, their preparation and use as medicaments | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| BR112012004851B8 (pt) | uso de um derivado de tiazol | |
| EA201101579A1 (ru) | Имидазо[1,2-а]пиридин-2-ил-фенил производные для лечения рака | |
| MX2008011020A (es) | Compuestos de receptor sigma. | |
| WO2006014703A3 (en) | Homopiperdinine derivatives as nk-1 antagonists | |
| EA200970293A1 (ru) | Новые производные 5-тиоксилопиранозы | |
| EA200701086A1 (ru) | Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли |